Nia Adeniji, Vinodhini Arjunan, Vijay Prabhakar, Ajitha Mannalithara, Tara Ghaziani, Aijaz Ahmed, Paul Kwo, Mindie Nguyen, Marc L Melcher, Ronald W Busuttil, Sander S Florman, Brandy Haydel, Richard M Ruiz, Goran B Klintmalm, David D Lee, C Burcin Taner, Maarouf A Hoteit, Elizabeth C Verna, Karim J Halazun, Amit D Tevar, Abhinav Humar, William C Chapman, Neeta Vachharajani, Federico Aucejo, Trevor L Nydam, James F Markmann, Constance Mobley, Mark Ghobrial, Alan N Langnas, Carol A Carney, Jennifer Berumen, Gabriel T Schnickel, Debra L Sudan, Johnny C Hong, Abbas Rana, Christopher M Jones, Thomas M Fishbein, Vatche Agopian, Renumathy Dhanasekaran
The incidence of hepatocellular carcinoma (HCC) is growing in the US, especially among the elderly. Older patients are increasingly getting transplanted for HCC, but the impact of advancing age on long-term post-transplant outcomes is not clear. To study this, we used data from the US Multicenter HCC Transplant Consortium (UMHTC) of 4980 patients. We divided the patients into 4 groups by age at transplantation- 18-64 (n = 4001), 65-69 (n = 683), 70-74 (n = 252) and ≥ 75 years (n = 44). There were no differences in HCC tumor stage, type of bridging locoregional therapy or explant residual tumor between the groups...
December 11, 2020: Liver Transplantation